Lumacras
(Соторасіб)
(120 mg)
(56)
(Таб)
Lumakras (sotorasib) 120 mg, 56 tablets, original
In Stock
Indication
Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy.6 It is additionally approved in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluorouracil-, oxaliplatin- and irinotecan-based chemotherapy. 8
-
Commercial name:Lumacras
-
Сhemical name:Соторасіб
-
Dosage:120 mg
-
Quantity:56
-
Release form:Таб
-
Производитель:Amgen, USA
No reviews yet